Kalif Eliyahu Sharon 4

What Happened
Kalif Eliyahu Sharon, Chief Financial Officer of Teva Pharmaceutical Industries Ltd (TEVA), sold 345,810 shares on February 26, 2026 in open-market/private sale transactions. The weighted-average sale price was $33.64, producing total proceeds of approximately $11,634,708. The reported sales were completed under a pre-established Rule 10b5-1 trading plan.

Key Details

• Transaction date: February 26, 2026; Form 4 filed March 2, 2026.
• Transaction type: Sale (S) — open market or private sale.
• Shares sold: 345,810; weighted-average price: $33.64. Individual sale prices ranged from $33.57 to $33.86.
• Proceeds: ~$11,634,708.
• Shares owned after the transaction: Not disclosed in the provided excerpt (see the full Form 4 for post-transaction holdings).
• Notable footnotes:
  • F2: Sale executed pursuant to a Rule 10b5-1 trading plan adopted Nov 26, 2025.
  • F3: Reported price is a weighted average; seller will provide breakdown of fills/prices upon request.
  • F1: Teva’s ordinary shares may be represented by American Depositary Shares (each currently represents one ordinary share).

Context
Insider sales are often routine (for diversification, liquidity, or tax reasons); a 10b5-1 plan indicates trades were pre-planned and can reduce concerns about trading on nonpublic information but does not reveal motivation. Purchases generally provide stronger signals of insider confidence than sales. For full details (post-transaction holdings, precise timing, and per-trade prices), consult the complete Form 4 (Accession: 0001193125-26-085343).